ADYNOVATE
Biological
Shire North American Group Inc
Total Payments
$2.7M
Transactions
1,903
Doctors
368
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $51,438 | 22 | 14 |
| 2023 | $290,905 | 56 | 14 |
| 2022 | $140,800 | 53 | 16 |
| 2021 | $91,305 | 77 | 6 |
| 2020 | $303,763 | 200 | 58 |
| 2019 | $512,394 | 445 | 126 |
| 2018 | $885,353 | 584 | 112 |
| 2017 | $456,617 | 466 | 111 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 1,279 | 90.4% |
| Consulting Fee | $192,202 | 58 | 7.0% |
| Travel and Lodging | $39,173 | 35 | 1.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,680 | 3 | 0.7% |
| Food and Beverage | $11,559 | 525 | 0.4% |
| Education | $80.89 | 3 | 0.0% |
Payments by Type
Research
$2.5M
1,279 transactions
General
$262,694
624 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII BAX 855 IN PREVIOUSLY UNTREATED PATIENTS PUPS AND MINIMALLY TREATED PATIENTS MTPS 6 YEARS WITH SEVERE HEMOPHILIA A FVIII 1 | Shire North American Group Inc | $914,659 | 1 |
| PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII (BAX 855) IN PREVIOUSLY UNTREATED PATIENTS (PUPS) AND MINIMALLY TREATED PATIENTS (MTPS) < 6 YEARS WITH SEVERE HEMOPHILIA A (FVIII < 1%) | Takeda Pharmaceuticals U.S.A., Inc. | $533,819 | 1 |
| A PHASE 3B CONTINUATION STUDY OF THE SAFETY AND EFFICACY OF PEGYLATED RECOMBINANT FACTOR VIII PEG-RFVIII BAX 855 IN PROPHYLAXIS OF BLEEDING IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A | Shire North American Group Inc | $467,960 | 0 |
| PHASE 3, PROSPECTIVE, RANDOMIZED, MULTI-CENTER CLINICAL STUDY COMPARING THE SAFETY AND EFFICACY OF BAX 855 FOLLOWING PK-GUIDED PROPHYLAXIS TARGETING TWO DIFFERENT FVIII TROUGH LEVELS IN SUBJECTS WITH SEVERE HEMOPHILIA A | Shire North American Group Inc | $235,532 | 2 |
| Joint Status and Bleeding Phenotype Characterization in Severe and Non-Severe Hemophilia A and B | Takeda Pharmaceuticals U.S.A., Inc. | $201,054 | 0 |
| IISR-2021-200159 FACTOR VIII FUNCTION ON PLATELETS AND MICROPARTICLES IN RELATION TO EMICIZUMAB | Takeda Pharmaceuticals U.S.A., Inc. | $44,135 | 0 |
| IISR-2021-200159 Factor VIII function on platelets and microparticles in relation to emicizumab | Takeda Pharmaceuticals U.S.A., Inc. | $44,135 | 0 |
| A PHASE 3, MULTI-CENTER, OPEN LABEL STUDY OF EFFICACY AND SAFETY OF PEGYLATED RFVIII BAX 855 IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A UNDERGOING SURGICAL OR OTHER INVASIVE PROCEDURES | Shire North American Group Inc | $19,486 | 0 |
| EVALUATION OF LONG-TERM SAFETY OF ADYNOVI/ADYNOVATE (ANTIHAEMOPHILIC FACTOR [RECOMBINANT] PEGYLATED, RURIOCTOCOG ALFA PEGOL) IN PATIENTS WITH HAEMOPHILIA A - AN ADYNOVI/ADYNOVATE POST-AUTHORISATION SAFETY STUDY (PASS) | Takeda Pharmaceuticals U.S.A., Inc. | $9,100 | 0 |
Top Doctors Receiving Payments for ADYNOVATE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $2.4M | 1,254 |
| , MD | Pediatric Hematology-Oncology | Aurora, CO | $30,383 | 15 |
| , M.D | Pediatric Hematology-Oncology | Los Angeles, CA | $23,750 | 8 |
| , M.D | Pediatrics | Houston, TX | $23,513 | 10 |
| , MD | Pediatric Hematology-Oncology | Peoria, IL | $22,683 | 14 |
| , MD | Pediatric Hematology-Oncology | Cincinnati, OH | $20,776 | 9 |
| , M.D., MSC | Internal Medicine | Winston Salem, NC | $16,003 | 21 |
| Cindy Leissinger | Specialist | New Orleans, LA | $14,658 | 8 |
| , M.D | Hematology | Los Angeles, CA | $11,800 | 2 |
| , MD | Pediatric Hematology-Oncology | Ann Arbor, MI | $11,692 | 6 |
| , M.D | Pediatric Hematology-Oncology | Chicago, IL | $11,317 | 7 |
| , MD | Pediatrics | Pasadena, CA | $9,711 | 3 |
| , MD | Hematology & Oncology | New York, NY | $9,443 | 3 |
| , MD | Pediatric Hematology-Oncology | Lexington, KY | $8,998 | 7 |
| , MD | Pediatrics | Detroit, MI | $8,830 | 4 |
| , MD, MS | Hematology & Oncology | Milwaukee, WI | $8,748 | 2 |
| Maissaa Janbain | Specialist | New Orleans, LA | $8,474 | 4 |
| , MD | Pediatric Hematology-Oncology | New Orleans, LA | $8,288 | 13 |
| , MD | Internal Medicine | Minneapolis, MN | $8,052 | 2 |
| Craig Kessler | Hematology & Oncology | Washington, DC | $7,244 | 2 |
| , MD | Hematology & Oncology | San Diego, CA | $7,162 | 3 |
| , M.D | Pediatrics | Oklahoma City, OK | $6,300 | 1 |
| , MD | Pediatrics | Dallas, TX | $3,850 | 2 |
| , MD | Pediatric Hematology-Oncology | Orange, CA | $1,650 | 3 |
| , M.D | Pediatrics | Nashville, TN | $1,600 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $2.7M
- Total Doctors 368
- Transactions 1,903
About ADYNOVATE
ADYNOVATE is a biological associated with $2.7M in payments to 368 healthcare providers, recorded across 1,903 transactions in the CMS Open Payments database. The primary manufacturer is Shire North American Group Inc.
Payment data is available from 2017 to 2024. In 2024, $51,438 was paid across 22 transactions to 14 doctors.
The most common payment nature for ADYNOVATE is "Unspecified" ($2.5M, 90.4% of total).
ADYNOVATE is associated with 9 research studies, including "PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII BAX 855 IN PREVIOUSLY UNTREATED PATIENTS PUPS AND MINIMALLY TREATED PATIENTS MTPS 6 YEARS WITH SEVERE HEMOPHILIA A FVIII 1" ($914,659).